| Literature DB >> 35268353 |
Desirée Colombo1, Carlos Suso-Ribera2, Isabel Ortigosa-Beltrán3, Javier Fernández-Álvarez2, Azucena García-Palacios2,4, Cristina Botella2,4.
Abstract
Behavioral activation (BA) is a structured psychotherapeutic approach for the treatment of major depressive disorder (MDD), which aims at increasing the engagement in activities that might bring enjoyment and meaning to patients' lives. Although a growing body of evidence supports the effectiveness of BA, enhancing the motivation and activity level of depressed patients is often challenging. In the present study, we explored the effectiveness of a brief BA treatment supported by virtual reality (VR) to facilitate the visualization and anticipation of four pleasurable activities that we tried to re-introduce in the patients' daily routine. To do so, we conducted a single-case experimental design with multiple baselines in a sample of patients with moderate to severe depressive symptoms. Three overlap analyses across participants and across behaviors were conducted to calculate the rate of improvement of each patient after the delivery of the intervention. Across the three overlap indices, the participants generally showed moderate-to-large improvements in the level of daily activity, as well as in the time spent planning and/or engaging in one or more activities scheduled during the intervention. Furthermore, most patients also reported a moderate-to-large reduction in daily depressive symptoms and improved mood. Overall, the promising results of the present study suggest that the proposed VR-based BA intervention might represent a valid approach to behaviorally activate depressed patients. The barriers and future lines of research of this innovative field are discussed.Entities:
Keywords: behavioral activation; depression; multiple baselines; single case experimental design; virtual reality
Year: 2022 PMID: 35268353 PMCID: PMC8911126 DOI: 10.3390/jcm11051262
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
Characteristics of the recruited sample.
| ID | Age | Sex | Medication | Group | PHQ-9 | PANAS-PA |
|---|---|---|---|---|---|---|
| 1 | 23 | f | No | 3 | 15 | 15 |
| 2 | 21 | f | No | 1 | 21 | 21 |
| 3 | 20 | f | No | 3 | 14 | 14 |
| 4 | 23 | m | Yes | 2 | 14 | 19 |
| 5 | 26 | f | No | 3 | 14 | 18 |
| 7 | 23 | f | Yes | 1 | 15 | 23 |
| 8 | 20 | f | No | 2 | 18 | 17 |
Group 1: 8 days of baseline (phase A), 23 days of treatment monitoring (phase B); Group 2: 9 days of baseline (phase A), 22 days of treatment monitoring (phase B); Group 3: 12 days of baseline (phase A) and 19 days of treatment monitoring (phase B). (PHQ-9 = Patient Health Questionnaire—9 items; PANAS-PA: Positive and Negative Affect Schedule—Positive Affect subscale).
Results of the NAP, PAND and PEM analyses across-participants in relation to the behavioral outcome variables.
| ID | Activity Level | BADS-BA | Savoring | ||||||
|---|---|---|---|---|---|---|---|---|---|
| NAP | PAND | PEM | NAP | PAND | PEM | NAP | PAND | PEM | |
| 1 | 80 * | 80 * | 87 * | 74 * | 72 * | 67 | 72 * | 76 * | 73 * |
| 2 | 76 * | 71 * | 79 * | 76 * | 76 * | 75 * | 72 * | 71 * | 75 * |
| 3 | 60 | 67 * | 64 | 66 * | 67 * | 64 | 61 | 67 * | 64 |
| 4 | 87 * | 86 * | 95 * | 53 | 77 * | 30 | 40 | 70 * | 33 |
| 5 | 80 * | 82 * | 100 * | 83 * | 79 * | 85 * | 85 * | 79 * | 82 * |
| 7 | 66 * | 67 * | 64 | 75 * | 76 * | 86 * | 78 * | 76 * | 71 * |
| 8 | 78 * | 89 * | 100 * | 83 * | 82 * | 86 * | 74 * | 86 * | 95 * |
| 6/7 | 7/7 | 5/7 | 6/7 | 7/7 | 4/7 | 5/7 | 7/7 | 5/7 | |
* = NAP indices over 66% (moderate-to-large effect); * = PAND indices over 64% (moderate-to-large effect); * = PEM indices over 70 (moderate-to-large effect). BADS-BA: Behavioral Activation for Depression Scale-Behavioral Activation subscale; NAP: non-overlap of all pairs; PAND: percentage of all non-overlapping data; PEM: percentage of data exceeding the median.
Results of the NAP, PAND and PEM analyses across-participants in relation to the affective outcome variables.
| ID | Daily Mood | PHQ2 | ||||
|---|---|---|---|---|---|---|
| NAP | PAND | PEM | NAP | PAND | PEM | |
| 1 | 70 * | 76 * | 87 * | 79 * | 76 * | 73 * |
| 2 | 89 * | 86 * | 93 * | 49 | 64 | 68 |
| 3 | 67 * | 71 * | 75 * | 66 * | 71 * | 43 |
| 4 | 42 | 70 * | 33 | 43 | 65 * | 50 |
| 5 | 67 * | 75 * | 76 * | 78 * | 79 * | 94 * |
| 7 | 88 * | 81 * | 93 * | 79 * | 81 * | 93 * |
| 8 | 79 * | 83 * | 90 * | 79 * | 79 * | 86 * |
| 6/7 | 7/7 | 6/7 | 5/7 | 6/7 | 4/7 | |
* = NAP indices over 66% (moderate-to-large effect); * = PAND indices over 64% (moderate-to-large effect); * = PEM indices over 70 (moderate-to-large effect). PHQ2: Patient Health Questionnaire—2; NAP: non-overlap of all pairs; PAND: percentage of all non-overlapping data; PEM: percentage of data exceeding the median.
Results of the NAP analyses across-behaviors in relation to the specific activity-related outcome variables.
| Motivation | Time Spent | Time Planning | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ID | Act. 1 | Act. 2 | Act. 3 | Act. 4 | Act. 1 | Act. 2 | Act. 3 | Act. 4 | Act. 1 | Act. 2 | Act. 3 | Act. 4 |
| 1 | 78 * | 79 * | 90 * | 90 * | 57 | 64 | 56 | 60 | 73 * | 67 * | 74 * | 79 * |
| 2 | 39 | 74 * | 36 | 41 | 93 * | 75 * | 58 | 76 * | 67 * | 60 | 64 | 73 * |
| 3 | 66 * | 95 * | 81 * | 65 | 53 | 49 | 84 * | 63 | 31 | 44 | 81 * | 58 |
| 4 | 87 * | 100 * | 99 * | 91 * | 47 | 50 | 50 | 46 | 53 | 66 * | 80 * | 39 |
| 5 | 65 | 64 | 45 | 20 | 71 * | 74 * | 62 | 42 | 62 | 65 | 65 | 58 |
| 7 | 17 | 22 | 45 | 36 | 67 * | 56 | 23 | 56 | 10 | 27 | 32 | 47 |
| 8 | 56 | 34 | 45 | 60 | 96 * | 66 * | 56 | 54 | 87 * | 45 | 52 | 40 |
* = NAP indices over 66% (moderate-to-large effect). Act: Activity.
Types of activities selected by each participant of the study.
| ID | Activity 1 | Activity 2 | Activity 3 | Activity 4 |
|---|---|---|---|---|
| 1 | 1 | 9 | 4 | 3 |
| 2 | 9 | 1 | 7 | 6 |
| 3 | 7 | 9 | 1 | 5 |
| 4 | 5 | 1 | 9 | 11 |
| 5 | 5 | 9 | 1 | 7 |
| 6 | 1 | 9 | 4 | 5 |
| 7 | 5 | 1 | 7 | 6 |